These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 12387809

  • 1. Controversies in the management of Kawasaki disease.
    Lang B, Duffy CM.
    Best Pract Res Clin Rheumatol; 2002 Jul; 16(3):427-42. PubMed ID: 12387809
    [Abstract] [Full Text] [Related]

  • 2. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment.
    Durongpisitkul K, Gururaj VJ, Park JM, Martin CF.
    Pediatrics; 1995 Dec; 96(6):1057-61. PubMed ID: 7491221
    [Abstract] [Full Text] [Related]

  • 3. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

  • 4. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
    J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [Abstract] [Full Text] [Related]

  • 5. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
    Sangtawesin C, Kirawitaya T, Layangkool T, Nawasiri W, Vimolsarawong N.
    J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S656-60. PubMed ID: 14700163
    [Abstract] [Full Text] [Related]

  • 6. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.
    Wooditch AC, Aronoff SC.
    Pediatrics; 2005 Oct; 116(4):989-95. PubMed ID: 16199713
    [Abstract] [Full Text] [Related]

  • 7. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
    Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
    [Abstract] [Full Text] [Related]

  • 8. A national survey on the pediatric cardiologist's clinical approach for patients with Kawasaki disease.
    Kahwaji IY, Connuck DM, Tafari N, Dahdah NS.
    Pediatr Cardiol; 2002 Feb; 23(6):639-46. PubMed ID: 12530498
    [Abstract] [Full Text] [Related]

  • 9. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial.
    Sundel RP, Baker AL, Fulton DR, Newburger JW.
    J Pediatr; 2003 Jun; 142(6):611-6. PubMed ID: 12838187
    [Abstract] [Full Text] [Related]

  • 10. A cost-benefit analysis of intravenous immunoglobulin treatment in children with Kawasaki disease.
    Arj-ong S, Chotivitayatarakorn P, Lertsapcharoen P, Khongphatthanayothin A, Thisyakorn C.
    J Med Assoc Thai; 2003 Jun; 86 Suppl 2():S179-88. PubMed ID: 12929987
    [Abstract] [Full Text] [Related]

  • 11. Intravenous Immunoglobulin for the Treatment of Kawasaki Disease.
    Shulman ST.
    Pediatr Ann; 2017 Jan 01; 46(1):e25-e28. PubMed ID: 28079915
    [Abstract] [Full Text] [Related]

  • 12. Immunoglobulin failure and retreatment in Kawasaki disease.
    Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C.
    Pediatr Cardiol; 2003 Jan 01; 24(2):145-8. PubMed ID: 12457253
    [Abstract] [Full Text] [Related]

  • 13. Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease.
    Lau AC, Duong TT, Ito S, Yeung RS.
    Arthritis Rheum; 2009 Jul 01; 60(7):2131-41. PubMed ID: 19565485
    [Abstract] [Full Text] [Related]

  • 14. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
    Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa H.
    Pediatr Infect Dis J; 2008 Feb 01; 27(2):155-60. PubMed ID: 18174868
    [Abstract] [Full Text] [Related]

  • 15. Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease.
    Sittiwangkul R, Pongprot Y, Silvilairat S, Phornphutkul C.
    Singapore Med J; 2006 Sep 01; 47(9):780-4. PubMed ID: 16924360
    [Abstract] [Full Text] [Related]

  • 16. Kawasaki disease: a comprehensive review of treatment options.
    Patel RM, Shulman ST.
    J Clin Pharm Ther; 2015 Dec 01; 40(6):620-5. PubMed ID: 26547265
    [Abstract] [Full Text] [Related]

  • 17. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
    DU ZD, Zhao D, DU JB, Lu S, Yi JM, Hou AC, Zhou ZS, Ding GF, Beijing Kawasaki Disease Epidemilogy Study Grou.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 27; 87(44):3119-21. PubMed ID: 18269869
    [Abstract] [Full Text] [Related]

  • 18. Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement.
    Simonini G, Masi L, Giani T, Piscitelli E, Cimaz R, Vierucci S, Brandi ML, Falcini F.
    J Rheumatol; 2005 Nov 27; 32(11):2233-8. PubMed ID: 16265708
    [Abstract] [Full Text] [Related]

  • 19. Intravenous immunoglobulin therapy induces neutrophil apoptosis in Kawasaki disease.
    Tsujimoto H, Takeshita S, Nakatani K, Kawamura Y, Tokutomi T, Sekine I.
    Clin Immunol; 2002 May 27; 103(2):161-8. PubMed ID: 12027421
    [Abstract] [Full Text] [Related]

  • 20. Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intravenous immune globulin.
    Leung DY.
    Clin Exp Immunol; 1996 May 27; 104 Suppl 1():49-54. PubMed ID: 8625544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.